Research ExplorerPublicationsPresence of bone marrow micro-metastases in stage I-III colo...

Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival

Standard

Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival. / Viehl, Carsten T; Weixler, Benjamin; Guller, Ulrich; Dell-Kuster, Salome; Rosenthal, Rachel; Ramser, Michaela; Banz, Vanessa; Langer, Igor; Terracciano, Luigi; Sauter, Guido; Oertli, Daniel; Zuber, Markus.

In: CANCER MED-US, Vol. 6, No. 5, 05.2017, p. 918-927.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Viehl, CT, Weixler, B, Guller, U, Dell-Kuster, S, Rosenthal, R, Ramser, M, Banz, V, Langer, I, Terracciano, L, Sauter, G, Oertli, D & Zuber, M 2017, 'Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival', CANCER MED-US, vol. 6, no. 5, pp. 918-927. https://doi.org/10.1002/cam4.1056

APA

Viehl, C. T., Weixler, B., Guller, U., Dell-Kuster, S., Rosenthal, R., Ramser, M., Banz, V., Langer, I., Terracciano, L., Sauter, G., Oertli, D., & Zuber, M. (2017). Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival. CANCER MED-US, 6(5), 918-927. https://doi.org/10.1002/cam4.1056

Vancouver

Viehl CT, Weixler B, Guller U, Dell-Kuster S, Rosenthal R, Ramser M et al. Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival. CANCER MED-US. 2017 May;6(5):918-927. https://doi.org/10.1002/cam4.1056

Bibtex

@article{389b7746510f43bca1946f3956955202,
title = "Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival",
abstract = "The prognostic significance of bone marrow micro-metastases (BMM) in colon cancer patients remains unclear. We conducted a prospective cohort study with long-term follow-up to evaluate the relevance of BMM as a prognostic factor for disease free (DFS) and overall survival (OS) in stage I-III colon cancer patients. In this prospective multicenter cohort study 144 stage I-III colon cancer patients underwent bone marrow aspiration from both iliac crests prior to open oncologic resection. The bone marrow aspirates were stained with the pancytokeratin antibody A45-B/B3 and analyzed for the presence of epithelial tumor cells. DFS and OS were analyzed using a Cox proportional hazard model and robust standard errors to account for clustering in the multicenter setting. Median overall follow-up was 6.2 years with no losses to follow-up, and 7.3 years in patients who survived. BMM were found in 55 (38%) patients. In total, 30 (21%) patients had disease recurrence and 56 (39%) patients died. After adjusting for known prognostic factors, BMM positive patients had a significantly worse DFS (hazard ratio [HR] 1.33; 95% confidence interval [95% CI]: 1.02-1.73; P = 0.037) and OS (HR 1.30; 95% CI: 1.09-1.55; P = 0.003) compared to BMM negative patients. Bone marrow micro-metastases occur in over one third of stage I-III colon cancer patients and are a significant, independent negative prognostic factor for DFS and OS. Future trials should evaluate whether node-negative colon cancer patients with BMM benefit from adjuvant chemotherapy.",
keywords = "Journal Article",
author = "Viehl, {Carsten T} and Benjamin Weixler and Ulrich Guller and Salome Dell-Kuster and Rachel Rosenthal and Michaela Ramser and Vanessa Banz and Igor Langer and Luigi Terracciano and Guido Sauter and Daniel Oertli and Markus Zuber",
note = "{\textcopyright} 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2017",
month = may,
doi = "10.1002/cam4.1056",
language = "English",
volume = "6",
pages = "918--927",
journal = "CANCER MED-US",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival

AU - Viehl, Carsten T

AU - Weixler, Benjamin

AU - Guller, Ulrich

AU - Dell-Kuster, Salome

AU - Rosenthal, Rachel

AU - Ramser, Michaela

AU - Banz, Vanessa

AU - Langer, Igor

AU - Terracciano, Luigi

AU - Sauter, Guido

AU - Oertli, Daniel

AU - Zuber, Markus

N1 - © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2017/5

Y1 - 2017/5

N2 - The prognostic significance of bone marrow micro-metastases (BMM) in colon cancer patients remains unclear. We conducted a prospective cohort study with long-term follow-up to evaluate the relevance of BMM as a prognostic factor for disease free (DFS) and overall survival (OS) in stage I-III colon cancer patients. In this prospective multicenter cohort study 144 stage I-III colon cancer patients underwent bone marrow aspiration from both iliac crests prior to open oncologic resection. The bone marrow aspirates were stained with the pancytokeratin antibody A45-B/B3 and analyzed for the presence of epithelial tumor cells. DFS and OS were analyzed using a Cox proportional hazard model and robust standard errors to account for clustering in the multicenter setting. Median overall follow-up was 6.2 years with no losses to follow-up, and 7.3 years in patients who survived. BMM were found in 55 (38%) patients. In total, 30 (21%) patients had disease recurrence and 56 (39%) patients died. After adjusting for known prognostic factors, BMM positive patients had a significantly worse DFS (hazard ratio [HR] 1.33; 95% confidence interval [95% CI]: 1.02-1.73; P = 0.037) and OS (HR 1.30; 95% CI: 1.09-1.55; P = 0.003) compared to BMM negative patients. Bone marrow micro-metastases occur in over one third of stage I-III colon cancer patients and are a significant, independent negative prognostic factor for DFS and OS. Future trials should evaluate whether node-negative colon cancer patients with BMM benefit from adjuvant chemotherapy.

AB - The prognostic significance of bone marrow micro-metastases (BMM) in colon cancer patients remains unclear. We conducted a prospective cohort study with long-term follow-up to evaluate the relevance of BMM as a prognostic factor for disease free (DFS) and overall survival (OS) in stage I-III colon cancer patients. In this prospective multicenter cohort study 144 stage I-III colon cancer patients underwent bone marrow aspiration from both iliac crests prior to open oncologic resection. The bone marrow aspirates were stained with the pancytokeratin antibody A45-B/B3 and analyzed for the presence of epithelial tumor cells. DFS and OS were analyzed using a Cox proportional hazard model and robust standard errors to account for clustering in the multicenter setting. Median overall follow-up was 6.2 years with no losses to follow-up, and 7.3 years in patients who survived. BMM were found in 55 (38%) patients. In total, 30 (21%) patients had disease recurrence and 56 (39%) patients died. After adjusting for known prognostic factors, BMM positive patients had a significantly worse DFS (hazard ratio [HR] 1.33; 95% confidence interval [95% CI]: 1.02-1.73; P = 0.037) and OS (HR 1.30; 95% CI: 1.09-1.55; P = 0.003) compared to BMM negative patients. Bone marrow micro-metastases occur in over one third of stage I-III colon cancer patients and are a significant, independent negative prognostic factor for DFS and OS. Future trials should evaluate whether node-negative colon cancer patients with BMM benefit from adjuvant chemotherapy.

KW - Journal Article

U2 - 10.1002/cam4.1056

DO - 10.1002/cam4.1056

M3 - SCORING: Journal article

C2 - 28401701

VL - 6

SP - 918

EP - 927

JO - CANCER MED-US

JF - CANCER MED-US

SN - 2045-7634

IS - 5

ER -